Explore
Validate
Learn
Western blot
Flow cytometryAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Flow cytometry [1]
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MAB1139-100 - Provider product page
- Provider
- R&D Systems
- Product name
- Human Siglec-9 Antibody
- Antibody type
- Monoclonal
- Description
- Protein A or G purified from hybridoma culture supernatant. Detects human Siglec-9 in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse Siglec-E is observed and less than 1% cross-reactivity with recombinant human (rh) Siglec-3, rhSiglec-5, rhSiglec-6, rhSiglec-7, rhSiglec-8 or rhSiglec-10 is observed. In Western blots, approximately 100% cross-reactivity with recombinant mouse Siglec-E is observed under non-reduced conditions.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antigen sequence
Q9Y336- Isotype
- IgG
- Antibody clone number
- 191240
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.
Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S
Cancer immunology research 2019 May;7(5):707-718
Cancer immunology research 2019 May;7(5):707-718
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.
Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H
The Journal of clinical investigation 2018 Nov 1;128(11):4912-4923
The Journal of clinical investigation 2018 Nov 1;128(11):4912-4923
Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response.
Carlin AF, Uchiyama S, Chang YC, Lewis AL, Nizet V, Varki A
Blood 2009 Apr 2;113(14):3333-6
Blood 2009 Apr 2;113(14):3333-6
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Detection of Siglec-9 in Human Blood Granulocytes by Flow Cytometry. Human peripheral blood granulocytes were stained with (A) Mouse Anti-Human Siglec-3/CD33 PE-conjugated Monoclonal Antibody (Catalog # FAB1137P) and (B) Mouse Anti-Human Siglec-9 Monoclonal Antibody (Catalog # MAB1139, filled histogram) or isotype control antibody (Catalog # MAB003, open histogram), followed by PerCP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0114).
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- Cell Adhesion Mediated by Siglec-9 and Neutralization by Human Siglec-9 Antibody. Recombinant Human Siglec-9 Fc Chimera (Catalog # 1139-SL), immobilized onto a microplate, supports the adhesion of human red blood cells in a dose-dependent manner (orange line). Adhesion elicited by Recombinant Human Siglec-9 Fc Chimera (10 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Human Siglec-9 Monoclonal Antibody (Catalog # MAB1139). The ND50 is typically 0.015-0.075 µg/mL.
